Sirt result, page-10

I stumbled across this article:
http://www.healio.com/hepatology/on...ernal-radiation-yield-similar-survival-in-hcc

I haven't compared the article and the below document published on the conference website in detail
https://ilc-congress.eu/wp-content/uploads/2017/04/GS012-Vilgrain.pdf

I did note this: The overall study population included 237 patients treated with SIRT and 222 patients treated with sorafenib. The data set included intention-to-treat (ITT), per protocol and safety populations.
Results of the ITT analysis showed that OS was 8 months in the SIRT group and 9.9 months for sorafenib (HR = 1.15; 95% CI, 0.94-1.41). For the per protocol analysis, the OS was 9.9 months in both groups (HR = 0.99; 95% CI, 0.79-1.24). “Subgroup analysis showed that OS was similar in subgroups like age, sex [and] severity of disease,” Vilgrain said.

Disclosure: not currently held, but held previously. I may seek to enter on Monday if the drop is significant. Good luck to all holders.